Back to results
US 12,571,027 B2Granted
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLorah Perlee, Sara Hamon, Charles Paulding
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.
Claims16
A method of treating a macular degeneration patient with a vascular endothelial growth factor (VEGF) inhibitor, comprising:
- administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 4 to 6 weeks when the patient does not have one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095;
- or administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient from about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 9 to 12 weeks when the patient has one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095.
Dependencies are inferred from the claim text.